Are you Dr. Butrynski?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 105 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
520 Country Club Pkwy
Eugene, OR 97401Phone+1 541-683-5001Fax+1 541-683-1422
Summary
- Dr. James Butrynski, MD is an oncologist in Eugene, Oregon. He is currently licensed to practice medicine in Oregon, Massachusetts, and Washington. He is affiliated with PeaceHealth Sacred Heart Medical Center at RiverBend and is an Instructor in Medicine at Dana-Farber Cancer Institute.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 1998 - 1998
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1996 - 1998
Massachusetts General HospitalResidency, Internal Medicine, 1993 - 1996
Wayne State University School of MedicineClass of 1993
Certifications & Licensure
OR State Medical License 2017 - 2025
WA State Medical License 1998 - 2017
MA State Medical License 2007 - 2015
MD State Medical License 1996 - 1998- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Continuous Temozolomide in Patients With Advanced or Metastatic Soft Tissue Sarcoma or Metastatic Breast Cancer Start of enrollment: 2000 Jul 01
- Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Start of enrollment: 2011 May 01
- Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas Start of enrollment: 2012 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 595 citationsCrizotinib in ALK-rearranged inflammatory myofibroblastic tumor.James E. Butrynski, David R. D'Adamo, Jason L. Hornick, Paola Dal Cin, Cristina R. Antonescu
The New England Journal of Medicine. 2010-10-28 - 117 citationsPhase II Study of the Safety and Antitumor Activity of the Hypoxia-Activated Prodrug TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue SarcomaSant P. Chawla, Lee D. Cranmer, Brian A. Van Tine, Damon R. Reed, Scott H. Okuno
Journal of Clinical Oncology. 2014-10-10 - 126 citationsCombination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid TumorsRichard Quek, Qian Wang, Jeffrey A. Morgan, Geoffrey I. Shapiro, James E. Butrynski
Clinical Cancer Research. 2011-02-15
Grant Support
- Novel Radioimmunotherapy For LymphomaNational Cancer Institute2000–2001
Professional Memberships
- Member
